Sorafenib use while waiting for liver transplant: We still need to wait

Journal of Hepatology

Volumn 56, Issue 3, 2012, Pages 723-725

  Finn, Richard S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SORAFENIB;

ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; DRUG SAFETY; HAZARD RATIO; HEMIHEPATECTOMY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER GRAFT REJECTION; LIVER REGENERATION; LIVER RESECTION; LIVER TRANSPLANTATION; METASTASIS; NONHUMAN; NOTE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR GROWTH;

EID: 84857365453     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2011.08.023     Document Type: Note

References (16)

1. J.M. Llovet Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
2. A.L. Cheng Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial Lancet Oncol 10 2009 25 34
3. Okita K, Imanaka K, Chida N, Tak WY, Nakachi K, Takayama T, et al. Phase III study of sorafenib in patients in Japan and Korea with advanced hepatocellular carcinoma (HCC) treated after transarterial chemoembolization (TACE). Abstract 128, 2010.
4. A. Vitale Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety Hepatology 51 2010 165 173
5. V. Mazzaferro Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis N Engl J Med 334 1996 693 699
6. I.W. Graziadei Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome Liver Transpl 9 2003 557 563
7. D.S. Lu Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation Hepatology 41 2005 1130 1137
8. P.A. Clavien, M. Lesurtel, P.M. Bossuyt, G.J. Gores, B. Langer, and A. Perrier Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report Lancet Oncol 2011 [Epub ahead of print]
9. D. Bose Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care Lancet Oncol 11 2010 373 382
10. C.L. Cowey Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma J Clin Oncol 28 2010 1502 1507
11. V. Margulis Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma J Urol 180 2008 94 98
12. C. Hora, P. Romanque, and J.F. Dufour Effect of sorafenib on murine liver regeneration Hepatology 53 2011 577 586
13. D. Strumberg Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors J Clin Oncol 23 2005 965 972
14. A.A. Miller Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301 J Clin Oncol 27 2009 1800 1805
15. J.M. Ebos Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Cancer Cell 15 2009 232 239
16. K. Hoffmann Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794] BMC Cancer 8 2008 349